In a significant move to address chronic kidney disease (CKD) complications, Zydus Lifesciences has announced a collaborative research agreement with the Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop an innovative oral medication targeting chronic kidney disease-induced osteoporosis. The partnership will focus on discovering small molecule
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Scopolamine Transdermal System 1 mg/3 days. (USRLD: Transderm Scop Transdermal System ® 1 mg/3 days). This is the
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) today announced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for MamitraTM, a Trastuzumab biosimilar. The drug will be marketed in different strengths
Rana was earlier with Sun Pharma Consumer Healthcare for 6 years as Head of Marketing & eCommerce Former Sun Pharma Consumer Healthcare senior executive Tarundeep Singh Rana has joined Zydus Healthcare Limited as the Chief Marketing Officer. He was with Sun Consumer Healthcare for 6 years
Four Posters accepted at The Liver Meeting® 2022 Two Posters are awarded the “AASLD Presidential Poster Of Distinction” Ahmedabad, India November 03, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company today announced that four abstracts on Saroglitazar Mg will be
Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Micafungin for Injection, 50 mg/vial and 100 mg/vial, single-dose vials (USRLD: Mycamine®). Micafungin for Injection is indicated to treat variety of fungal infections. It
Healthy Growth in FDI and Digital Initiatives further fueling growth of Domestic Pharma Industry India’s $42 billion pharmaceutical sector is heavily dependent on China for key active pharmaceutical ingredients or API — chemicals that are responsible for the therapeutic effect of drugs. Various estimates put India’s dependence
Zydus, an innovation driven global pharma major and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC™ is a critical drug to treat Mucormycosis
